Helge Bischoff

机构：Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, Hautklinik Heidelberg, Frauenklinik Heidelberg, German Center for Lung Research · ORCID：0000-0002-7693-0058

发表论文 131 篇 · 总被引 16934 次 · h-index 35

代表论文

• Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study (2023 · Journal of Clinical Oncology · 被引 715)
• Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 (2021 · Annals of Oncology · 被引 426)
• Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial (2022 · Journal of Thoracic Oncology · 被引 128)
• Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial (2022 · The Lancet Respiratory Medicine · 被引 124)
• Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer (2021 · ESMO Open · 被引 102)
• RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 40)